Which of the following is/are FDA-approved labeled indication(s) for Metoclopramide Hydrochloride? Select all that apply.

A. Depression is primarily managed with selective serotonin reuptake inhibitors or other antidepressant classes to modulate monoamine neurotransmission. Metoclopramide acts as a dopamine D2 receptor antagonist and is not indicated for mood disorders. Its use in psychiatric conditions is restricted. B. Gastroesophageal reflux is an approved indication for symptomatic relief when conventional therapy fails. Metoclopramide increases lower esophageal sphincter tone and stimulates upper gastrointestinal tract motility. It facilitates gastric emptying to prevent acid reflux into the distal esophagus. C. Anxiolytic properties are characteristic of benzodiazepines or certain antihistamines that depress the central nervous system. Metoclopramide lacks the GABA-ergic modulation required to reduce clinical anxiety. The drug is classified as a prokinetic and antiemetic agent, not a psychotropic. D. Diabetic gastroparesis is a labeled indication where the drug alleviates symptoms like nausea and delayed gastric emptying. By antagonizing dopamine receptors and sensitizing tissues to acetylcholine, it restores gastrointestinal motility. This enhances the transit of food in diabetic patients.